Table 2: Role of IL-28B in HCV treatment.

IL-28B  SNPPR (IDEAL)Telaprevir (advance)Boceprevir (SPRINT-2)
ITT populationAdherent populationTVR/PRPR controlBOC/PR*PR control

CC69%79%90%64%80–82%78%
CT33%38%71%25%65–71%28%
TT27%26%73%23%55–59%27%

*Includes BOC/RGT and BOC/PR48 arms [61, 69, 80, 81].